APY Aspyra,

Aspyra, Inc. (AMEX:APY) announced today that the Company has entered into agreements with several customers to upgrade their existing Aspyra CyberLAB LIS system to the latest product release. Aspyra customers that have recently signed upgrade agreements include: Porter Hospital, Inc. (Middlebury, VT), Pathology & Clinical Laboratory Snd Bhd (Selangor, Malaysia), and IGeneX, Inc. (Palo Alto, CA), will be upgrading their existing Aspyra CyberLAB LIS� to the current 7.2 version. Aspyra�s CyberLAB LIS is a scalable, feature-rich, and cost-effective LIS solution for hospital, clinic, and reference laboratory settings. CyberLAB 7.2 is available on a Windows platform, utilizing a MS SQL database structure. CyberLAB LIS features decision support tools with auto-verification, automated clinical reporting and multisite management. �We continue to see an influx of activity within the laboratory marketplace. This is likely attributed to the dwindling population of medical technologists and the number of legacy systems in the marketplace, necessitating the need for improved productivity tools within the LIS. Aspyra continues to enhance our LIS with feature sets such as our decision support rules and automated reporting capabilities, that enable our customers to improve workflow and turnaround,� stated Michelle Del Guercio, Aspyra Director of Marketing and Product Management. About Aspyra Aspyra is a global provider of Health Care Information Technology (HCIT) solutions and services to the healthcare industry. The Company specializes in Clinical Information Systems (CIS), Picture Archive Communication Systems (PACS) and Clinical Image Management Systems (CIMS) for hospitals, multi-specialty clinics, clinical laboratories, imaging departments and centers and orthopedic environments. Aspyra's highly scalable systems can be installed standalone or integrated to provide a single-vendor, enterprise-wide solution. For more information on Aspyra, its products and services, visit www.aspyra.com. Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. Such statements are based upon, among other things, assumptions made by, and information currently available to, management as of the date of this release, including management's own knowledge and assessment of the Company's industry, customers and competition. Factors that could cause Aspyra's actual results to differ materially from these forward-looking statements include among others: changes in the Company�s management or other personnel, the competitive environment for Company products and services; unexpected technical and marketing difficulties inherent in major product development efforts; the potential need for changes in the Company�s long-term strategy in response to future developments; future advances in clinical information technology and procedures, as well as potential changes in government regulations and healthcare policies; and rapid technological change in the microelectronics and software industries. The Company refers interested persons to its most recent Annual Report on Form 10-KSB and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.